Phase II studies of mitozolomide in melanoma, lung and ovarian cancer
- 1 May 1989
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 25 (5) , 785-788
- https://doi.org/10.1016/0277-5379(89)90121-1
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Phase II evaluation of mitozolomide in ovarian cancerBritish Journal of Cancer, 1988
- Mitozolomide (NSC 353451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced diseaseBritish Journal of Cancer, 1987
- Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.Journal of Clinical Oncology, 1986
- ACTIVITY OF MITOZOLOMIDE (NSC 353451), A NEW IMIDAZOTETRAZINE, AGAINST XENOGRAFTS FROM HUMAN MELANOMAS, SARCOMAS, AND LUNG AND COLON CARCINOMAS1985
- PHASE-I CLINICAL-TRIAL OF MITOZOLOMIDE1985
- ANTITUMOR IMIDAZOTETRAZINES .6. EXPERIMENTAL ANTITUMOR-ACTIVITY AGAINST MURINE TUMOR-MODEL SYSTEMS OF 8-CARBAMOYL-3-(2-CHLOROETHYL)IMIDAZO[5,1-D]-1,2,3,5-TETRAZIN-4(3H)-ONE(MITOZOLOMIDE), A NOVEL BROAD-SPECTRUM AGENT1985
- Antitumour imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, a novel broad-spectrum antitumor agentJournal of Medicinal Chemistry, 1984
- Small cell carcinoma of the lungCancer Treatment Reviews, 1982
- DTIC THERAPY IN METASTATIC MALIGNANT-MELANOMA - A SIMPLIFIED DOSE SCHEDULE1980